Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 471 (3), 355-362

Neuron navigator-2 and Cyclin D2 Are New Candidate Prognostic Markers in Uterine Sarcoma

Affiliations

Neuron navigator-2 and Cyclin D2 Are New Candidate Prognostic Markers in Uterine Sarcoma

Ben Davidson et al. Virchows Arch.

Abstract

The objective of this study was to validate the diagnostic and clinical role of four protein products of genes previously found to be differentially expressed in uterine low-grade endometrial stromal sarcoma (LG-ESS) compared to uterine leiomyosarcoma (LMS). Protein expression by immunohistochemistry of transgelin (TGLN), neuron navigator-2 (NAV2), fatty acid binding protein-3 (FABP3), and cyclin D2 (CCND2) was analyzed in 305 uterine sarcomas (231 LMS, 74 LG-ESS). Expression was analyzed for association with clinicopathologic parameters and survival. TGLN (p < 0.001), NAV2 (p < 0.001), and FABP3 (p = 0.005) were overexpressed in LMS compared to LG-ESS, whereas nuclear CCND2 (p < 0.001) was overexpressed in LG-ESS. NAV2 expression was associated with shorter overall survival in patients with LMS (p = 0.037), whereas nuclear CCND2 expression in LG-ESS was significantly related to longer survival (p = 0.012) in univariate analysis. Nuclear CCND2 expression was an independent prognosticator in Cox multivariate analysis (p = 0.023). In conclusion, TGLN, FABP3, NAV2, and nuclear CCND2 aid in differentiating LG-ESS from LMS. NAV2 and CCND2 are novel candidate prognostic markers in LMS and LG-ESS, respectively.

Keywords: Diagnosis; Immunohistochemistry; Survival; Uterine sarcoma.

Similar articles

See all similar articles

References

    1. J Exp Clin Cancer Res. 2015 Oct 09;34:117 - PubMed
    1. Mod Pathol. 2013 Apr;26(4):502-10 - PubMed
    1. Am J Surg Pathol. 2011 Nov;35(11):1626-37 - PubMed
    1. J Pathol. 1999 Oct;189(2):194-200 - PubMed
    1. Mod Pathol. 2009 Jun;22(6):786-96 - PubMed

MeSH terms

Feedback